December 1, 2021

Survival benefit was shown with the combination of niraparib and rucaparib in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

Julie R. Brahmer, MD, MSc, FASCO, cochair of the upcoming 19th Annual Winter Lung Cancer Conference, has seen the full development of immunotherapy era in lung cancer from the beginning.

ATR’s integral role in DNA damage repair has made it an appealing target for cancer treatment, and several ATR inhibitors are being evaluated for efficacy and safety across solid tumors.

During a conference presentation, A. Oliver Sartor, MD, explained how researchers are building upon the principles of T-cell redirecting agents, such as bispecific T-cell engagers, from other cancer types for the sake of treating patients with prostate cancer.

Updated findings from the phase 1/2 TRIDENT-1 trial evaluating repotrectinib showed efficacy in patients with neurotrophic tyrosine receptor kinase fusion-positive advanced solid tumors in expanded cohorts.

Investigators reported meaningful pharmacodynamic and pharmacokinetic observations of BT5528 treatment, suggesting tumor penetration in a standard 3+ 3 dose-escalation trial.

Javier L. Munoz, MD, MBA, discussed best options and timing for treating chronic lymphocytic leukemia now and beyond the pandemic

According to Ajjai S. Alva, MBBS, CDK12 is a cell cycle gene that has an important role in RNA polymerase 2 and immunotherapy activity.

Recent genomic profiling studies revealed that approximately 40% of patients with biliary tract cancers harbor actionable genomic mutations.